WEBULL
WebtradeDownload

Terumo (TSE:4543) Lifted Its Guidance, Is It Fully Priced?

Simply Wall St · 2d ago

Why Terumo stock is back in focus after the latest guidance update

Terumo (TSE:4543) moved back onto investor radars after record-high quarterly revenue, a sharp jump in net income and an upward revision to full year earnings guidance tied partly to US tariff related gains.

See our latest analysis for Terumo.

Terumo’s strong quarterly earnings and higher profit guidance have been met with a sharp rebound in sentiment, with the stock posting a 34.64% 90 day share price return while the 1 year total shareholder return is still down 5.81%. Recent momentum is therefore rebuilding from a weaker long term base.

If this mix of renewed momentum and earlier share price weakness has you looking beyond Terumo, it could be a good moment to scan for other healthcare leaders using our screener for 6 healthcare AI stocks

For Terumo, the recent jump in the share price sits between a stronger profit outlook and a reset in sentiment after last year’s decline. How does that balance show up in today’s valuation?

Most Popular Narrative: 8.3% Overvalued

Terumo last closed at ¥2,598.5 while the most followed narrative puts fair value at ¥2,400, using a discount rate of 5.43% to frame that gap.

The assumed bearish price target for Terumo is ¥2400.0, which represents up to two standard deviations below the consensus price target of ¥3023.08. This valuation is based on what can be assumed as the expectations of Terumo's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.

Read the complete narrative.

Want to see what supports that lower fair value on Terumo? The narrative focuses on measured revenue growth, rising margins and a richer future earnings multiple.

Result: Fair Value of ¥2,400 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors still need to factor in risks such as tighter price controls in China and rising global competition, which could put pressure on Terumo’s margins and growth assumptions.

Find out about the key risks to this Terumo narrative.

Another view on Terumo’s valuation

The most followed narrative has Terumo slightly overvalued at ¥2,400, yet the current P/E of 23.3x tells a different story. It sits well below the peer average of 49.5x and also below a 27x fair ratio that the market could eventually lean toward. Which signal would you put more weight on?

See what the numbers say about this price — find out in our valuation breakdown.

TSE:4543 P/E Ratio as at Aug 2026
TSE:4543 P/E Ratio as at Aug 2026

Next Steps

If the mixed signals around Terumo leave you undecided, this is the moment to review the data yourself and move quickly to shape your own view. A helpful place to start is a balanced snapshot that sets out 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Terumo?

If Terumo has sharpened your focus on quality, do not stop here. Use the Simply Wall St screener to quickly spot fresh opportunities that suit your style.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.